Antiretroviral medications disrupt microglial phagocytosis of -amyloid and increase its production by neurons: Implications for HIV-associated neurocognitive disorders

Molecular Brain

Volumn 4, Issue 1, 2011, Pages

  Giunta, Brian ^a   Ehrhart, Jared ^a   Obregon, Demian F ^a   Lam, Lucy ^a   Le, Lisa ^a   Jin, Jingji ^a   Fernandez, Francisco ^a   Tan, Jun ^a   Shytle, R Douglas ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

antiretrovirals; cognitive disorders; HIV; microglial cells

Indexed keywords

ABACAVIR; AMYLOID BETA PROTEIN[1-42]; CELL PROTEIN; FLUORESCEIN ISOTHIOCYANATE; INDINAVIR; LAMIVUDINE; ZIDOVUDINE; AMYLOID BETA PROTEIN; ANTIRETROVIRUS AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COGNITION; DRUG EFFECT; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; CELL LINE; COGNITIVE DEFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

MURINAE;

AIDS DEMENTIA COMPLEX; AMYLOID BETA-PEPTIDES; ANTI-RETROVIRAL AGENTS; CELL LINE; COGNITION DISORDERS; HIV INFECTIONS; HIV-1; HUMANS; MICROGLIA; NEURONS; PHAGOCYTOSIS;

EID: 79957963432     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-4-23     Document Type: Article

References (24)

1. Clinical aspects of psychoneuroimmunology. K Goodkin MA Fletcher N Cohen, Lancet 1995 345 8943 183 4 7823677
2. HIV-1 infection and cognitive impairment in the cART era: a review. J Schouten,, et al. AIDS 2011 25 5 561 75 10.1097/QAD.0b013e3283437f9a 21160410
3. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Xu T Ikezu, J Neuroimmune Pharmacol 2009 4 2 200 12 10.1007/s11481-008-9136-0 19016329
4. Elevated expression of IFN-gamma (Pubitemid 39060830)
5. HIV-1 associated dementia: symptoms and causes. M Ghafouri,, et al. Retrovirology 2006 3 28 10.1186/1742-4690-3-28 16712719
6. The neuropathogenesis of AIDS. F Gonzalez-Scarano J Martin-Garcia, Nat Rev Immunol 2005 5 1 69 81 10.1038/nri1527 15630430 (Pubitemid 40070332)
7. Aging Hearing: HIV over fifty, exploring the new threat. 2005 (Senate Committee on Aging)
8. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. KR Robertson,, et al. Neurology 2010 74 16 1260 6 10.1212/WNL.0b013e3181d9ed09 20237308
9. HIV, antiretroviral therapies, and the brain. KJ Liner MJ Ro KR Robertson, Curr HIV/AIDS Rep 2010 7 2 85 91 10.1007/s11904-010-0042-8 20425562
10. Prevalence of Alzheimer plaques in AIDS. MM Esiri SC Biddolph CS Morris, J Neurol Neurosurg Psychiatry 1998 65 1 29 33 10.1136/jnnp.65.1.29 9667557 (Pubitemid 28302353)
11. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. HC Rempel L Pulliam, AIDS 2005 19 2 127 35 10.1097/00002030-200501280-00004 15668537 (Pubitemid 40409531)
12. Neurodegeneration and ageing in the HAART era. BJ Brew,, et al. J Neuroimmune Pharmacol 2009 4 2 163 74 10.1007/s11481-008-9143-1 19067177
13. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. CL Achim,, et al. J Neuroimmune Pharmacol 2009 4 2 190 9 10.1007/s11481-009-9152-8 19288297
14. HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. B Giunta,, et al. Int J Clin Exp Pathol 2008 1 3 260 75 18784813
15. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. KP Townsend,, et al. Eur J Immunol 2005 35 3 901 10 10.1002/eji.200425585 15688347 (Pubitemid 40425546)
16. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 (World Health Organization)
17. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. RK Heaton,, et al. Neurology 2010 75 23 2087 96 10.1212/WNL.0b013e318200d727 21135382
18. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. LA Cysique BJ Brew, Neuropsychol Rev 2009 19 2 169 85 10.1007/s11065-009-9092-3 19424802
19. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. BC Schweinsburg,, et al. J Neurovirol 2005 11 4 356 64 10.1080/13550280591002342 16206458 (Pubitemid 41614515)
20. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. H Dou,, et al. J Immunol 2009 183 1 661 9 10.4049/jimmunol.0900274 19535632
21. Mitochondria, Amyloid beta, and Alzheimer's Disease. RD Readnower AD Sauerbeck PG Sullivan, Int J Alzheimers Dis 2011 2011 104545 21547208
22. HIV and antiretroviral therapy in the brain: neuronal injury and repair. R Ellis D Langford E Masliah, Nat Rev Neurosci 2007 8 1 33 44 10.1038/nrn2040 17180161 (Pubitemid 46011997)
23. Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. M Kiebala,, et al. PLoS One 2010 5 7 11875 10.1371/journal.pone.0011875 20686703
24. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Y Liu,, et al. Nat Med 2000 6 12 1380 7 10.1038/82199 11100124 (Pubitemid 32001023)